Roy Brian D, Bourgeois Jacqueline M, Mahoney Douglas J, Tarnopolsky Mark A
Division of Neurology, Department of Medicine, 1200 Main St. W., McMaster University, Hamilton, ON L8N 3Z5, Canada.
Can J Physiol Pharmacol. 2002 Oct;80(10):1008-14. doi: 10.1139/y02-129.
Corticosteroids are used as chemotherapeutic agents in many medical conditions, despite many common and potentially serious side effects. Supplementation with creatine monohydrate (CrM) can increase strength and lean body mass in humans and, therefore, may be a viable countermeasure to the side effects of corticosteroids. Therefore, the purpose of this study was to determine if CrM could prevent the attenuation of growth associated with corticosteroid administration. Forty male Sprague-Dawley rats were randomized to the following groups: control (CON, n = 10), 7 mg methylprednisolone x kg(-1) x week(-1) (PRED, n = 10), 2% CrM in diet (CD, n = 10), or CrM and methylprednisolone (CD-PRED, n = 10). Animals received either a weekly sham injection (saline; CON and CD) or an injection of methylprednisolone (PRED and CD-PRED) for 6 weeks. At the completion of the 6th week, body composition was determined and skeletal muscles were collected. Weight gain was attenuated in PRED as compared with all other groups (P < 0.05). Muscle total creatine and phosphocreatine were greater in the extensor digitorum longus in the CD and CD-PRED groups as compared with the CON and PRED groups (P < 0.05); however, total creatine and phosphocreatine in the soleus were not different. Mean fiber area was greater in type II fibers from the extensor digitorum longus in the CD and CD-PRED groups as compared with the CON and PRED groups (P < 0.05); no treatment effect was seen in the soleus. In conclusion, CrM supplementation prevented the attenuation of growth associated with corticosteroids and also increased type II muscle fiber area. These results could have important clinical implications for several patient populations commonly treated with corticosteroids, and further work is required to determine the specific mechanisms underlying the physiological effects that were observed.
尽管皮质类固醇有许多常见且可能严重的副作用,但在许多医疗状况下仍被用作化疗药物。补充一水肌酸(CrM)可以增加人体的力量和瘦体重,因此,它可能是应对皮质类固醇副作用的一种可行对策。因此,本研究的目的是确定CrM是否能够预防与皮质类固醇给药相关的生长减缓。将40只雄性Sprague-Dawley大鼠随机分为以下几组:对照组(CON,n = 10)、7毫克甲基泼尼松龙×千克⁻¹×周⁻¹(PRED,n = 10)、饮食中含2% CrM(CD,n = 10),或CrM与甲基泼尼松龙组(CD-PRED,n = 10)。动物接受每周一次的假注射(生理盐水;CON和CD)或甲基泼尼松龙注射(PRED和CD-PRED),持续6周。在第6周结束时,测定身体成分并收集骨骼肌。与所有其他组相比,PRED组的体重增加减缓(P < 0.05)。与CON组和PRED组相比,CD组和CD-PRED组的趾长伸肌中的肌肉总肌酸和磷酸肌酸含量更高(P < 0.05);然而,比目鱼肌中的总肌酸和磷酸肌酸没有差异。与CON组和PRED组相比,CD组和CD-PRED组的趾长伸肌II型纤维的平均纤维面积更大(P < 0.05);比目鱼肌未观察到治疗效果。总之,补充CrM可预防与皮质类固醇相关的生长减缓,还可增加II型肌纤维面积。这些结果可能对几种常用皮质类固醇治疗的患者群体具有重要的临床意义,需要进一步开展工作以确定所观察到的生理效应背后的具体机制。